Premium
F3‐02‐01: Soluble abnormally hyperphosphorylated tau
Author(s) -
Alonso Alejandra,
Corbo Christopher,
Beharry Cindy
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.1126
Subject(s) - microtubule , tau protein , neurodegeneration , axoplasmic transport , microbiology and biotechnology , cytoskeleton , tubulin , chemistry , phosphorylation , biology , neuroscience , cell , alzheimer's disease , biochemistry , pathology , medicine , disease
is associated with an increased risk of cognitive decline, the impact of amyloid-positivity on the likelihood and timing of clinical progression to AD dementia on an individual basis remains unknown. We are developing safeguards based on the REVEAL study and consent language to convey the uncertainty of the clinical implications of amyloid-status in asymptomatic individuals. We also plan to imbed an ethics substudy in the A4 trial to evaluate the short and long-term impact of learning one’s amyloid status (positive or negative). Alternative designs being considered by other prevention trial initiatives in genetic-risk subjects include randomizing non-mutation carriers to receive placebo only.Conclusions: The advent of secondary prevention trials in preclinical AD populations requires careful consideration of the issues of revealing biomarker results in asymptomatic populations. These trials provide an important research opportunity to evaluate the impact of learning one’s amyloid status in the setting of incomplete knowledge regarding the future clinical implications, and the factors that influence the response to this information.